Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Regina Beets-Tan in Mission Board for Cancer van nieuwe EU-Kaderprogramma
aug 2019